Compare Ascendis Pharma A/S (ASND) vs Mercadolibre Inc (MELI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Mercadolibre Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Mercadolibre Inc trades at $1,854 (market cap $93.90B). The key difference: Mercadolibre Inc is far larger — about 5.3× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Mercadolibre Inc nearer its low. Which is the better fit depends on your goals.
| ASND | MELI | |
|---|---|---|
Market Cap | $17.74B | $93.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $2.51K |
52-Week Low | $163.32 | $1.55K |
Enterprise Value | $18.11B | $100.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
MercadoLibre (MELI) trades at $1,852.22, up 2.46% today, with a bullish technical signal from moving averages and strong analyst support (23 buy, 0 sell). Revenue grew to $28.89B in 2025, though net income margin compressed to 6.04% amid heavy investment. Recent news highlights investigations by law firms and debates over profitability versus growth, while cash flow from operations surged to $12.12B.
Outlook remains positive given dominant Latin American e-commerce position and 49% revenue growth, but risks include margin pressure from capex, legal scrutiny, and high valuation multiples. The consensus price target of $2,230 implies ~20% upside, contingent on execution amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
